10 results on '"Michelet, Christian"'
Number of results to display per page
Search Results
2. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
- Author
-
Maillard A, Chapplain JM, Tribut O, Bentué-Ferrer D, Tattevin P, Arvieux C, Michelet C, and Ruffault A
- Subjects
- Adult, Aged, Cohort Studies, Female, Genotype, HIV Infections blood, HIV Infections virology, HIV Protease Inhibitors blood, HIV-1 enzymology, Humans, Lopinavir, Male, Middle Aged, Pyrimidinones blood, Retrospective Studies, Ritonavir blood, Sensitivity and Specificity, Viral Load, Algorithms, Drug Resistance, Viral, HIV Infections drug therapy, HIV Protease Inhibitors therapeutic use, HIV-1 genetics, Pyrimidinones therapeutic use, Ritonavir therapeutic use
- Abstract
Background: Different approaches using genotypic, pharmacokinetic parameters or combination of both have been recently developed to monitor antiretroviral treatment in HIV-1-infected individuals. Their uses in clinical practice may improve the benefit of protease inhibitor-based salvage therapy while reducing treatment toxicity and emergence of viral resistance., Objectives: To assess the prediction of genotypic inhibitory quotient (GIQ) using different genotypic drug resistance interpretation's algorithms and lopinavir plasma concentration in PI-experienced patients treated by lopinavir/ritonavir (LPV/r). Genotypic susceptibility score (GSS) was also evaluated., Study Design: Forty-seven HIV-1 PI-experienced, but LPV naïve patients were included in a retrospective cohort study. Plasma HIV-1 viral load (VL), CD4 cell count and LPV plasma concentrations were assessed at weeks (W) 12 and 24. Interpretation of baseline resistance genotype was achieved according to four different algorithms and GSS calculated using two expert systems. GIQ was defined as the ratio of LPV concentration to the number of LPV resistance mutations at day 0 (D0) and patients classified by units of GIQ. The end point of the study was the virological response expressed in HIV VL median decrease from D0 to W24., Results: The overall median VL decrease from D0 to W24 was -2.42 log(10)copies/mL and 60% of patients had VL below 400 copies/mL. The LPV mutation score was predictive of response for all algorithms whereas plasma concentrations of LPV were not. Mean VL decrease was greater for higher GIQ classes and difference reached statistical significance at W24. When considering virological response at W24, GSS calculated with ANRS and Stanford system were good predictor scores as areas under the receiver operating characteristics (ROC) curves were 0.76 for both., Conclusion: GIQ was found to be a useful drug-monitoring tool which could be helpful in targeting LPV concentrations in order to achieve long-term undetectable viral load, particularly in genotypic resistant patients.
- Published
- 2007
- Full Text
- View/download PDF
3. Simultaneous quantitative assay of atazanavir and 6 other HIV protease inhibitors by isocratic reversed-phase liquid chromatography in human plasma.
- Author
-
Tribut O, Verdier MC, Arvieux C, Allain H, Michelet C, and Bentué-Ferrer D
- Subjects
- Atazanavir Sulfate, Humans, Chromatography, High Pressure Liquid methods, HIV Protease Inhibitors blood, Oligopeptides blood, Pyridines blood
- Abstract
Several liquid chromatography methods for assay of antiretroviral drugs in human plasma have been described, but none included atazanavir. The authors describe a user-friendly, validated, and rapid technique, derived from a procedure the authors have already published, allowing simultaneous quantification of amprenavir, indinavir, lopinavir, nelfinavir (and its M8 metabolite), ritonavir, saquinavir, efavirenz, and nevirapine. Assays were performed after diethyl ether liquid-liquid extraction from 250 microL plasma samples. Chromatographic separation was achieved on an X-TERRA column using a 58% water (with 3 mM pyrrolidine) and 42% acetonitrile mobile phase; 240 nm ultraviolet wavelength was used for atazanavir detection. This method has been in routine use in our laboratory for antiretroviral drug monitoring and now allows quantitative assay of a novel HIV protease inhibitor, atazanavir, with satisfactory intra- and interassay precision (CV<12%).
- Published
- 2005
- Full Text
- View/download PDF
4. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
- Author
-
Lamotte C, Landman R, Peytavin G, Mentre F, Gerbe J, Brun-Vezinet F, Boue F, Spiridon G, Valantin MA, Michelet C, Farinotti R, and Yeni P
- Subjects
- Adult, Aged, CD4 Lymphocyte Count, Capsules, Drug Therapy, Combination, Female, Gels, HIV Infections drug therapy, HIV Infections immunology, HIV Infections virology, HIV Protease Inhibitors pharmacokinetics, HIV Protease Inhibitors therapeutic use, HIV-1 drug effects, HIV-1 physiology, Humans, Male, Middle Aged, Pilot Projects, Prospective Studies, RNA, Viral blood, Ritonavir pharmacokinetics, Ritonavir therapeutic use, Saquinavir pharmacokinetics, Saquinavir therapeutic use, Treatment Outcome, Viral Load, HIV Protease Inhibitors administration & dosage, Ritonavir administration & dosage, Saquinavir administration & dosage
- Abstract
This was a prospective pilot study evaluating a saquinavir (SQV) soft-gel capsules (SGC)/ritonavir (RTV)-containing once-daily regimen over a follow-up of 3 months. The primary end-point was to determine the number of patients both remaining on treatment at month 3 and with trough SQV plasma concentration 24 h after the last intake (C24h) exceeding the inhibition of 95% of viral replication in vitro (IC95). The secondary end-points were to investigate the immuno-virological efficacy and safety of SQV-SGC/RTV once daily, and to explore SQV concentrations in peripheral blood mononuclear cells (PBMCs). Twenty-three antiretroviral-naive and 17 protease inhibitors (PIs) experienced HIV-1-infected patients with plasma HIV-1 RNA level below 200 copies/ml were enrolled. They were assigned to SQV-SGC/RTV (1600/100 mg once daily) combined with nucleoside and/or non-nucleoside reverse transcriptase inhibitors. In a subgroup of 13 patients, both plasma and intracellular SQV concentrations were determined. By intent to treat analysis the percentage of success at month 3 was 87.5% (confidence interval: 73.2-95.8%) with 78.3% in naive and 100% in PI-experienced patients. SQV C24h and intracellular concentrations [median (range, n)] were 241 ng/ml (40-1209, 35) and 323 ng/ml (168-475, 12), respectively. Intracellular concentrations showed an accumulation of SQV in PBMCs persisting during 24 h. Neither immunological nor virological failure was observed. Clinical and biological tolerance was acceptable in all patients but three with adverse effects leading to discontinuation. These data confirmed the short-term efficacy of SQV-SGC/RTV once-daily regimen based on SQV therapeutic drug monitoring.
- Published
- 2004
5. Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography.
- Author
-
Tribut O, Arvieux C, Michelet C, Chapplain JM, Allain H, and Bentué-Ferrer D
- Subjects
- Chromatography, High Pressure Liquid methods, Drug Monitoring, Humans, Reproducibility of Results, Sensitivity and Specificity, HIV Protease Inhibitors blood, Reverse Transcriptase Inhibitors blood
- Abstract
A rapid (less than 30 min), sensitive, and specific liquid chromatography method for simultaneous assay of nine antiretroviral drugs in human plasma is described. This technique allows therapeutic drug monitoring of six approved protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) and two approved non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine). Assays were performed after diethyl ether liquid-liquid extraction from 250-microL plasma samples. Chromatographic separation was achieved on an X-TERRA (Waters; Saint Quentin, France) column using a 58% water (with 3 mmol/L pyrrolidine) and 42% acetonitrile mobile phase. Three ultraviolet wavelengths were used for detection with a diode array detector. This method allowed quantitative assay of all nine antiretroviral drugs within a concentration range of 25 ng/mL to 9000 ng/mL. The method has been validated extensively and has been in routine use in our laboratory for several months for drug monitoring in plasma samples from patients treated with antiretroviral drugs.
- Published
- 2002
- Full Text
- View/download PDF
6. Salvage therapy with amprenavir and ritonavir: prospective study in 17 heavily pretreated patients.
- Author
-
Arvieux C, Tattevin P, Souala FM, Jaccard P, Ruffault A, Bentué-Ferrer D, Tribut O, Chapplain JM, Dupont M, Bouvier C, and Michelet C
- Subjects
- Adult, Anti-HIV Agents adverse effects, CD4 Lymphocyte Count, Carbamates, Drug Resistance, Viral genetics, Drug Therapy, Combination, Female, Furans, Genotype, HIV Protease Inhibitors adverse effects, Humans, Male, Middle Aged, Patient Compliance, Phenotype, Prospective Studies, Ritonavir adverse effects, Sulfonamides adverse effects, Treatment Outcome, Viral Load, Anti-HIV Agents therapeutic use, HIV Infections drug therapy, HIV Protease Inhibitors therapeutic use, HIV-1 drug effects, HIV-1 genetics, HIV-1 immunology, Ritonavir therapeutic use, Salvage Therapy, Sulfonamides therapeutic use
- Abstract
Objective: To evaluate the safety profile and efficacy of salvage regimens containing amprenavir (APV) 600 mg twice daily and ritonavir (RTV) 200 mg twice daily., Design: Prospective, single-center study., Method: The patient database of the department of infectious diseases was screened for patients who had failed at least two successive three-drug combinations. These patients were proposed to take APV and RTV in association with two to four other drugs. They were followed monthly for 6 months., Results: Seventeen patients were included. They had been previously treated for 70 +/- 23 months. At baseline, viral load (VL) was 4.86 +/- 0.98 log10 copies/mL and CD4 187 +/- 145 10(6)/L. On week 24, using intent-to-treat analysis, VL decreased to 2.95 +/- 1.59 log10 copies/mL and CD4 increased to 365 +/- 210 10(6)/L. Nine patients (53%) had a VL < 2.3 log10 copies/mL. The most common adverse events were grade 1 or 2 diarrhea and an increase of cholesterol and triglyceride levels. Mean APV trough concentration was 1727 +/- 1749 ng/mL on week 24., Conclusion: These data show that the combination of low-dose RTV and reduced doses of APV is safe. This combination can be added to nonnucleoside analogs.
- Published
- 2002
- Full Text
- View/download PDF
7. Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen.
- Author
-
Le Moing V, Thiébaut R, Chêne G, Leport C, Cailleton V, Michelet C, Fleury H, Herson S, and Raffi F
- Subjects
- Adult, Female, HIV Infections immunology, HIV Infections virology, Humans, Male, Patient Compliance, Prospective Studies, RNA, Viral blood, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, HIV Infections drug therapy, HIV Protease Inhibitors therapeutic use
- Abstract
The temporal relationships between plasma human immunodeficiency virus (HIV) RNA levels and evolution of CD4(+) cell counts was studied, using a 2-slope longitudinal mixed model, in 988 patients prospectively enrolled at the initiation of a protease inhibitor--containing regimen of antiretroviral therapy. The short-term slope (baseline through month 4) for mean change in CD4(+) cell count was +21.2 cells/mm(3)/month, and the long-term slope (month 4 through month 24) was +5.5 cells/mm(3)/month. Compared with results from patients without viral response, the long-term slope was 2.5 cells/mm(3)/month higher in patients who had plasma HIV RNA levels of <500 copies/mL at month 4 (P <.001). It was significantly lower after a rebound in plasma HIV RNA level to > or = 500 copies/mL (P <.0001), varied according to plasma HIV RNA level at the time of rebound, and was negative only when the plasma HIV RNA level at rebound was > or = 10,000 copies/mL. If CD4(+) cell counts can remain elevated despite virologic treatment failure, such a discrepant response may be transient in patients who have a high plasma HIV RNA level at the time of treatment failure.
- Published
- 2002
- Full Text
- View/download PDF
8. Incidence, Medical and Socio-Behavioural Predictors of Psychiatric Events in An 11-Year Follow-Up of HIV-Infected Patients on Antiretroviral Therapy
- Author
-
Protopopescu, Camelia, Raffi, François, Brunet-François, Cécile, Salmon, Dominique, Verdon, Renaud, Reboud, Philippe, Carrieri, Maria Patrizia, Leport, Catherine, Spire, Bruno, Michel, Laurent, Michelet, Christian, Aix Marseille Université (AMU), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Maladies infectieuses et tropicales, Service de médecine interne et centre de référence des maladies rares [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Unité de Maladies Infectieuses et Tropicales [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Troubles du comportement alimentaire de l'adolescent (UMR_S 669), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), APROCO-COPILOTE (ANRS CO8) Study Group, Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Sud - Paris 11 (UP11)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques, Aix Marseille Université ( AMU ), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale ( SESSTIM - U912 INSERM - AMU - IRD ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Service des maladies infectieuses et tropicales, CHU Caen, Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Troubles du comportement alimentaire de l'adolescent ( UMR_S 669 ), Université Paris-Sud - Paris 11 ( UP11 ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut de recherche, santé, environnement et travail ( Irset ), Université d'Angers ( UA ) -Université de Rennes 1 ( UR1 ), and Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -École des Hautes Études en Santé Publique [EHESP] ( EHESP ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ) -Université des Antilles ( UA )
- Subjects
Male ,MESH: CD4 Lymphocyte Count ,Epidemiology ,HIV Infections ,MESH : Viral Load ,0302 clinical medicine ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Surveys and Questionnaires ,Immunopathology ,Hiv infected patients ,Pharmacology (medical) ,Longitudinal Studies ,MESH: Incidence ,MESH: Treatment Outcome ,MESH: Middle Aged ,Depression ,MESH: HIV ,Incidence ,MESH : HIV Protease Inhibitors ,MESH: Follow-Up Studies ,MESH: HIV Infections ,MESH : Incidence ,3. Good health ,Suicide ,[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Drug Therapy, Combination ,Viral disease ,Infection ,0305 other medical science ,MESH: Social Behavior ,medicine.medical_specialty ,03 medical and health sciences ,MESH : HIV Infections ,Humans ,MESH : Middle Aged ,Antiviral ,Social Behavior ,Pharmacology ,MESH: Humans ,MESH: Questionnaires ,MESH : Humans ,MESH : Follow-Up Studies ,MESH: Adult ,MESH : Proportional Hazards Models ,medicine.disease ,Antiretroviral agent ,MESH: Female ,Immune deficiency ,MESH : Social Behavior ,MESH : HIV ,MESH: Proportional Hazards Models ,Risk Factors ,MESH : Depression ,MESH: Risk Factors ,MESH : Female ,030212 general & internal medicine ,MESH: Longitudinal Studies ,MESH : Longitudinal Studies ,MESH : Suicide ,Incidence (epidemiology) ,MESH : Questionnaires ,Middle Aged ,Viral Load ,MESH : Adult ,MESH : Risk Factors ,AIDS ,Treatment Outcome ,Infectious Diseases ,Female ,France ,MESH: Viral Load ,Adult ,MESH: Depression ,MESH : Male ,MESH : Treatment Outcome ,Acquired immunodeficiency syndrome (AIDS) ,MESH : CD4 Lymphocyte Count ,medicine ,Chemotherapy ,MESH : France ,Psychiatry ,Proportional Hazards Models ,MESH: HIV Protease Inhibitors ,030505 public health ,Potential risk ,business.industry ,MESH : Drug Therapy, Combination ,HIV ,HIV Protease Inhibitors ,Antiretroviral therapy ,MESH: Male ,CD4 Lymphocyte Count ,Treatment ,MESH: France ,MESH: Drug Therapy, Combination ,MESH: Suicide ,Predictive factor ,business ,Follow-Up Studies - Abstract
Background Psychiatric disorders are relatively common among HIV-infected patients. However, there are few studies about their potential risk factors. This analysis aimed to measure the incidence of severe psychiatric events (PE) among patients receiving combination antiretroviral therapy (cART) of the French APROCO-COPILOTE (ANRS CO8) cohort, and to identify the medical and socio-behavioural correlates of their first episode of depression, suicide or suicide attempt (D/S/SA). Methods APROCO-COPILOTE is a cohort of patients started on a protease inhibitor regimen between 1997 and 1999, with prospective medical standardized records and self-administered questionnaires collecting socio-demographic and socio-behavioural data. This analysis included all 11-year follow-up visits for 1,095 patients having completed baseline self-administered questionnaires. A proportional hazard Cox model was used to identify the correlates of a first D/S/SA event. Results The overall prevalence of severe PE remained low: 50 patients experienced 67 events (incidence rate [95% CI] =1.04 [0.82, 1.32] per 100 person-years). Depression ( n=16), suicides ( n=5) and suicide attempts ( n=14) were the most frequently diagnosed PE (0.54 [0.39, 0.76] per 100 person-years) among 25 patients. Multivariate results showed that unemployment, unstable housing, detectable viral load and smoking more than 20 cigarettes/day were independently associated with D/S/SA. Conclusions Although the incidence of severe PE remained relatively low among the patients of APROCO-COPILOTE cohort, this study's results underline a clinically important problem in HIV-infected patients receiving cART. Furthermore, our findings not only emphasize the importance of comprehensive care, especially for socially vulnerable patients, but may also help future studies designed to assess the effectiveness of interventions in reducing the risk of PE during cART.
- Published
- 2012
- Full Text
- View/download PDF
9. Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial
- Author
-
Fagard, Catherine, Colin, Céline, Charpentier, Charlotte, Rami, Agathe, Jacomet, Christine, Yeni, Patrick, Vittecoq, Daniel, Katlama, Christine, Molina, Jean-Michel, Descamps, Diane, Chêne, Geneviève, Yazdanpanah, Yazdan, Michelet, Christian, Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Virologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Impacts de la puissance antivirale des antirétroviraux et de la résistance virale sur les stratégies thérapeutiques des infections par les virus de l'immunodéficience humaine, Université Paris Diderot - Paris 7 (UPD7), Service des Maladies Infectieuses et Tropicales, AP-HP, Hôpital Paul Brousse, Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des Maladies Infectieuses et Tropicales, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Modélisation, Aide à la Décision, et Coût-Efficacité en Maladies Infectieuses (ATIP-Avenir Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), French National Agency for Research on AIDS and Viral Hepatitis (ANRS), ANRS 139 TRIO Trial Group, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], and Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
- Subjects
Male ,Enfuvirtide ,MESH: Sulfonamides ,Etravirine ,HIV Infections ,Pharmacology ,Raltegravir Potassium ,0302 clinical medicine ,MESH: Drug Resistance, Multiple, Viral ,Pharmacology (medical) ,030212 general & internal medicine ,Darunavir ,0303 health sciences ,Sulfonamides ,MESH: Middle Aged ,biology ,MESH: Follow-Up Studies ,MESH: HIV Infections ,Middle Aged ,Pyrrolidinones ,3. Good health ,Pyridazines ,Infectious Diseases ,MESH: RNA, Viral ,Lentivirus ,RNA, Viral ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Female ,raltegravir ,medicine.drug ,Adult ,medicine.medical_specialty ,MESH: Pyrrolidinones ,03 medical and health sciences ,Drug Resistance, Multiple, Viral ,Internal medicine ,MESH: Pyridazines ,Nitriles ,medicine ,Humans ,darunavir/ritonavir ,etravirine ,MESH: HIV Protease Inhibitors ,Ritonavir ,MESH: Humans ,030306 microbiology ,business.industry ,multidrug resistant ,HIV ,MESH: Adult ,HIV Protease Inhibitors ,Raltegravir ,biology.organism_classification ,MESH: Male ,Regimen ,Pyrimidines ,MESH: Ritonavir ,business ,MESH: Female ,Follow-Up Studies - Abstract
International audience; Among 103 patients with multidrug-resistant HIV who initiated raltegravir, etravirine, and darunavir/ritonavir-containing regimen in the ANRS 139 TRIO trial, 100 participated in extended follow-up and continued study treatment until week 96. Among them, 87 (87%) received an optimized background therapy including either nucleoside reverse transcriptase inhibitors or enfuvirtide, they were 78 (78%) at week 96. At week 96, 88% achieved durable virologic response (
- Published
- 2012
- Full Text
- View/download PDF
10. Transmitted drug resistance in French HIV-2-infected patients
- Author
-
Charpentier, Charlotte, Visseaux, Benoit, Bénard, Antoine, Peytavin, Gilles, Damond, Florence, Roy, Céline, Taieb, Audrey, Chêne, Geneviève, Matheron, Sophie, Brun-Vézinet, Francoise, Descamps, Diane, Michelet, Christian, Laboratoire de Virologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de pharmacie, Service des maladies infectieuses et tropicales, Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), ANRS CO5 HIV-2 Cohort, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 (UPD7), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), and Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
- Subjects
medicine.medical_treatment ,Immunology ,Human immunodeficiency virus (HIV) ,HIV Infections ,Drug resistance ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,Drug Resistance, Viral ,Prevalence ,medicine ,Humans ,Immunology and Allergy ,030212 general & internal medicine ,0303 health sciences ,Protease ,030306 microbiology ,business.industry ,Survey research ,HIV Protease Inhibitors ,Virology ,Reverse transcriptase ,Confidence interval ,3. Good health ,Infectious Diseases ,[SDV.TOX]Life Sciences [q-bio]/Toxicology ,HIV-2 ,Cohort ,RNA, Viral ,Reverse Transcriptase Inhibitors ,France ,business - Abstract
International audience; We report the first transmitted drug resistance survey study in HIV-2-infected patients living in France. The prevalence of transmitted drug resistance was 5.0% (95% confidence interval, 0.1-9.9) with mutations detected only in protease, not in reverse transcriptase. In this series, 10% of patients displayed X4/dual-mixed viruses. These findings classified the rate of transmitted drug resistance in the HIV-2 French Cohort as low prevalence.
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.